Last reviewed · How we verify

NCT03863379: SarcObeNDS

Sarcopenic Obesity in Neurodisabilities

Completed Last updated 27 January 2023
What this trial tests

trial testing whole body DXA in Sarcopenic Obesity in 150 participants. Completed in 15 May 2022.

Timeline
2 May 2019
Primary endpoint
15 June 2021
15 May 2022

Quick facts

Lead sponsorDionyssiotis, Yannis, M.D.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date2 May 2019
Primary completion15 June 2021
Estimated completion15 May 2022
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Dionyssiotis, Yannis, M.D.

Who can join

Adults 20 to 90, any sex, with Sarcopenic Obesity or Spinal Cord Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To describe the frequency and thresholds for sarcopenic obesity in neurodisabled persons and the fat and lean mass distribution based on various neurodisabilities

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Sarcopenic Obesity in Individuals With Neurodisabilities: The SarcObeNDS Study.
    Dionyssiotis Y, Prokopidis K, Trovas G, Papadatou MC, et al · · 2022 · cited 2× · PMID 35928890 · DOI 10.3389/fendo.2022.868298
  2. Communications to the International Sarcopenia Translational Research Conference 2021.
    · 2021 · PMID 34557616 · DOI 10.22540/jfsf-06-163

Verify or expand the search:

Other recruiting trials for Sarcopenic Obesity

Currently open trials in the same condition.

Other Dionyssiotis, Yannis, M.D. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03863379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing